News

In this month's Clinical Round Up, Sharon Freedman, MD, discusses results of the Infant Aphasia Treatment Study, and how it found there is no glaucoma protection from primary IOL placement in children. Additionally, Barbara Parolini, MD, discusses the new hope for better myopic traction maculopathy outcomes.

Optimizing Procedures with the LenSx® Laser. Published as a promotional supplement to Ophthalmology Times, September 2015.

Change is inevitable. But that doesn’t have to mean the beginning of problems and stress at your practice.

Nutritional supplements can improve colour vision, contrast sensitivity and other measures of visual functioning in people with diabetes -- with or without retinopathy, researchers say.

In her latest blog, Georgette Pascale gives advice to the ophthalmic industry on rising above the noise and getting noticed to improve patient care.

British veterans with visual impairment suffer from high rates of mental disorder, according to researchers from King's College, London.

Do you know which famous figures are your ophthalmic colleagues?

Surgeons need to truly understand the ins and outs of their patients' personalities to optimize surgical outcomes, argues Mark Packer, MD, in his latest blog.

Five years after adopting an electronic health record (EHR) system, a North Carolina ophthalmology practice saw a 41% return on investment, and netted roughly $1.2 million in revenue, according to a new report.

There were some gainers and some losers from last year. But who was named the best of the best for 2015?

New strategies for assessment of functional impairment will help clinicians and patients better understand how eye diseases affect driving and other activities of daily living.

Imbalance between IOP and cerebrospinal fluid pressure may influence the risk of normal-tension glaucoma or the susceptibility of the optic nerve to ocular hypertension.

n this installment of Sight Lines, J.C. Noreika, MD, MBA, talks with Michael L. Stark, JD, who has represented physicians for more than 50 years as his primary client base. Among the topics they discuss is the watershed moment that enabled physicians to incorporate and take advantage of business-tax deduction provisions.

Low perfusion pressure is a risk factor for glaucoma, however, the understanding of the role of perfusion pressure in the disease must be clarified.

Cornea experts discuss the roles of ocular surface transplantation and keratoprosthesis implantation in the management of eyes with severe limbal stem cell deficiency.

Beyond the official handbook, employees will also come with their own “rules of survival” that they expect the clinic to follow. Unfortunately, the practice will have no idea what the rules-or deviation of the rules-are until they occur.

Microstent implantation had favorable and safe results in a group of patients with open-angle glaucoma in the DUETTE trial.

Eyes undergoing implantation with an investigational Schlemm’s canal microstent at the time of cataract surgery achieve significantly greater IOP control than eyes having cataract surgery alone.

Switching from brand to generic eye drops for surgical prophylaxis following cataract surgery caused no difference in endophthalmitis rates and resulted in substantial cost savings in a single-center comparison.

: Highlights are presented from what is believed to be the first head-to-head comparison of one, two, and three stents inserted as a stand-alone procedure.

Findings from basic science research elucidating the mechanisms of retinal ganglion cell axon degeneration, regeneration, and death have identified new therapeutic targets for glaucoma that are being investigated in preclinical and clinical studies.

Capturing clinical images with the integration of electronic health records and smartphone applications can enhance practice efficiency and compliance.

The initial 36-month results are highlighted from a novel, soft and permanent, minimally invasive ab interno collagen implant used to optimize aqueous drainage to the subconjunctival space.

A potent and selective transforming growth factor (TGF)-β2 LNA-modified antisense oligonucleotide induces biologic responses consistent with the drug’s expected molecular mechanism of action in different preclinical ocular surface disease models.

A proprietary glaucoma device has changed current thinking about cyclophotocoagulation by offering another option in the glaucoma treatment algorithm and allowing earlier laser intervention when medical treatment comes up short.

Following specific steps in the retail-selling process will increase the likelihood that customers will make a purchase.

Active research in neuroprotection, neuroregeneration, and sustained drug delivery is expected to lead to better options for management of glaucoma.

Endoscopic cyclophotocoagulation with vitrectomy and pars plana treatment is effective in reducing IOP in patients with ultra-refractory glaucoma, reducing the need for medications and being relatively well tolerated by patients.